E76.22
Sanfilippo mucopolysaccharidoses
Clinical Classification Guidelines
Inclusion Terms
- Mucopolysaccharidosis, type III (A) (B) (C) (D)
- Sanfilippo A syndrome
- Sanfilippo B syndrome
- Sanfilippo C syndrome
- Sanfilippo D syndrome
Medical Intelligence & Overview
Sanfilippo mucopolysaccharidoses, also known as Mucopolysaccharidosis type III, is a rare genetic disorder that affects the body's ability to break down certain complex sugars. These sugars, called mucopolysaccharides, build up in the body over time, leading to progressive physical and neurological problems. The condition includes different subtypes—Sanfilippo A, B, C, and D—each caused by a specific enzyme deficiency responsible for breaking down these sugars.
Causes & Symptoms
Clinical Causes: Inheriting mutations in specific genes responsible for producing enzymes needed to degrade mucopolysaccharides Autosomal recessive inheritance pattern, meaning both parents must carry and pass on the defective gene Genetic testing can identify mutations linked to the different subtypes of Sanfilippo syndrome
Key Symptoms: Delayed developmental milestones Speech and language delays Behavioral problems such as hyperactivity or aggression Dementia-like decline as the disease progresses Severe sleep disturbances Sanfilippo-specific physical features like coarse facial features, enlarged liver and spleen, and skeletal abnormalities Progressive loss of motor skills Seizures in some cases
Diagnostic & Treatment
Diagnosis Path: Diagnosis often involves a combination of clinical evaluation and specialized tests, including enzymatic assays to measure enzyme activity levels and genetic testing to identify mutations. Urine tests may also demonstrate increased levels of mucopolysaccharides, indicating storage issues. Early diagnosis can help in managing symptoms and planning supportive care.
Treatment Protocols: Currently, there is no cure for Sanfilippo mucopolysaccharidoses. Management focuses on alleviating symptoms and improving quality of life, which may include behavioral therapies, physical therapy, and medications to address specific issues. Experimental treatments like enzyme replacement therapy or gene therapy are under investigation. Regular medical monitoring is essential for addressing complications as they arise.
Clinical Advice & FAQs
Billing Guidance
Is E76.22 a billable ICD-10 code?
Yes, E76.22 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report E76.22?
Clinical documentation must specify the nature of Sanfilippo mucopolysaccharidoses and any associated comorbidities for accurate reporting.
Cite this Clinical Reference